1. Median progression-free survival was 56.0 months in the olaparib group and was 13.8 months in the placebo group. 2. ...
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients ...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. ...
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients ...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. ...
